The stock of Foghorn Therapeutics Inc (FHTX) has gone up by 13.14% for the week, with a 23.54% rise in the past month and a 49.73% rise in the past quarter. The volatility ratio for the week is 6.99%, and the volatility levels for the past 30 days are 7.34% for FHTX. The simple moving average for the past 20 days is 14.90% for FHTX’s stock, with a -0.28% simple moving average for the past 200 days.
Is It Worth Investing in Foghorn Therapeutics Inc (NASDAQ: FHTX) Right Now?
The stock has a 36-month beta value of 3.05. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for FHTX is 27.90M, and at present, short sellers hold a 5.26% of that float. On July 10, 2025, the average trading volume of FHTX was 126.92K shares.
FHTX) stock’s latest price update
Foghorn Therapeutics Inc (NASDAQ: FHTX) has experienced a rise in its stock price by 12.68% compared to its previous closing price of $4.89. However, the company has seen a gain of 13.14% in its stock price over the last five trading days. globenewswire.com reported 2025-05-22 that CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen’s 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Analysts’ Opinion of FHTX
Many brokerage firms have already submitted their reports for FHTX stocks, with Citizens JMP repeating the rating for FHTX by listing it as a “Mkt Outperform.” The predicted price for FHTX in the upcoming period, according to Citizens JMP is $9 based on the research report published on April 23, 2025 of the current year 2025.
B. Riley Securities, on the other hand, stated in their research note that they expect to see FHTX reach a price target of $10. The rating they have provided for FHTX stocks is “Buy” according to the report published on January 30th, 2025.
Jefferies gave a rating of “Buy” to FHTX, setting the target price at $18 in the report published on September 03rd of the previous year.
FHTX Trading at 23.72% from the 50-Day Moving Average
After a stumble in the market that brought FHTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.24% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FHTX starting from Costa Carlos, who sale 35,756 shares at the price of $10.04 back on Sep 20 ’24. After this action, Costa Carlos now owns 0 shares of Foghorn Therapeutics Inc, valued at $358,990 using the latest closing price.
Costa Carlos, the Chief People Officer of Foghorn Therapeutics Inc, sale 857 shares at $10.17 during a trade that took place back on Sep 23 ’24, which means that Costa Carlos is holding 0 shares at $8,716 based on the most recent closing price.
Stock Fundamentals for FHTX
Current profitability levels for the company are sitting at:
- -4.14 for the present operating margin
- 1.0 for the gross margin
The net margin for Foghorn Therapeutics Inc stands at -3.42. The total capital return value is set at -0.52.
Based on Foghorn Therapeutics Inc (FHTX), the company’s capital structure generated -1.3 points at debt to capital in total, while cash flow to debt ratio is standing at -2.73.
Currently, EBITDA for the company is -97.17 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 11.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.16.
Conclusion
To sum up, Foghorn Therapeutics Inc (FHTX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
